Search

Displaying results 2041 - 2050 of 10000 in total
  1. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who

  2. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively … [L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]

    Categories: Drugs Used in Erectile DysfunctionSynonyms: (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamide
  3. Drug

    Maribavir

    go.drugbank.com/drugs/DB06234
    ApprovedInvestigational

    Maribavir was approved by the FDA in November 2021, under the name Livtencity (Takeda), for the treatment of resistant CMV infections in post-transplant patients. … Maribavir is an inhibitor of the cytomegalovirus (CMV; HHV5) pUL97 kinase which is used to treat CMV infections in patients post-transplantation.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.

  5. Indication

    Bone Diseases, Infectious

    go.drugbank.com/conditions/DBCOND0076351
    Drugs: Cephalexin · Tobramycin
    Synonyms: Infection in Bone
  6. Indication

    Diabetes Mellitus

    go.drugbank.com/conditions/DBCOND0027886
    Drugs: Ammonium chloride · Borneol · Insulin aspart · Insulin degludec · Insulin glargine · Insulin glulisine +4 more
    Synonyms: Ketoacidosis in diabetes mellitus
  7. Indication

    Insomnia

    go.drugbank.com/conditions/DBCOND0017531
    Drugs: Amitriptyline · Brotizolam · Butabarbital · Cinolazepam · Clotiazepam · Daridorexant +31 more
    Synonyms: Difficulty in sleep initiation
  8. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L52380] In June 2025, its US indication was expanded to include patients 18-59 years old at increased risk of disease.

  9. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    in combination with sofosbuvir for all six genotypes of Hepatitis C [L852]. … Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050

    Mixtures: Trijardy XR, Trijardy XRCategories: Drugs Used in Diabetes, DPP-IV Inhibitors